Episode
The FDA’s Peptide Crossroads: Will Regulation Clean Up the Gray Market—or Drive It Deeper Underground?
- Podcast
- The Energy Code
- Published
- Jul 13, 2026
- Duration seconds
- 2289
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-energy-code-2136601/episodes/the-fda-s-peptide-crossroads-will-regulation-clean-up-the-gray-market-or-drive-it-deeper-underground/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-energy-code-2136601/the-fda-s-peptide-crossroads-will-regulation-clean-up-the-gray-market-or-drive-it-deeper-underground.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this Deep Dive, Dr. Mike Belkowski examines the darker side of the rapidly growing peptide movement: unregulated sourcing, research-use-only products, online dosing communities, peptide stacking, questionable testing, and the widening gap between consumer experimentation and medical oversight. The episode begins with a recent review exploring how the success of GLP-1 drugs helped normalize self-injection and created an “Ozempic halo” around experimental peptides. Dr. Mike breaks down the digital peptide exposure pathway, the legal fiction of research-use-only labels, the risks of informal titration, and why a certificate of analysis may not confirm sterility, endotoxin safety, potency, or the quality of the vial actually being used. The second half turns to the FDA Pharmacy Compounding Advisory Committee’s July 23–24 review of BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon for possible inclusion on the Section 503A Bulks List. Dr. Mike explains what the proceeding does — and does not — mean, the FDA staff’s preliminary opposition, and three possible outcomes: favorable inclusion, rejection, or a substance-by-substance split decision. Ultimately, the central question is not whether peptide experimentation will continue. It is whether it will occur through accountable medical systems that improve testing and surveillance — or move further into an anonymous gray market operating beyond meaningful oversight. (Educational content only, not medical advice.) - Article Discussed in Episode: Unregulated Peptide Use in the Age of Biohacking: Digital Promotion, Gray-Market Access, and Emerging Public Health Risks - Key Quotes From Dr. Mike: “(Peptides) are relatively safe in the right hands — but can you really trust the sourcing and the quality?” “A certificate of an…